New drug aims to stop CMV from coming back after transplant
NCT ID NCT06407232
First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 23 times
Summary
This study tests whether the drug letermovir can prevent cytomegalovirus (CMV) from coming back in kidney or kidney/pancreas transplant patients who are at high risk. About 90 adults will take letermovir daily for 84 days and be followed for 6 months. The goal is to see if it reduces the number of CMV flare-ups and the need for other treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYTOMEGALOVIRUS INFECTIONS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UW Hospital and Clinics
RECRUITINGMadison, Wisconsin, 53792, United States
Contact
Contact
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Letermovir (Prevymis)
What this could lead to
If successful, letermovir could offer a new way to prevent CMV from coming back after treatment in transplant patients, reducing the need for other antiviral drugs.
What could go wrong
This is a phase 3 trial with only 90 participants, so results may not apply to everyone. Letermovir may not work as well as hoped, and side effects are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.